TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2973 participants.

Also called NCT03296813

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,973 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03296813
Other papers using this trial's data
  • Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial Journal of cardiac failure, 2022-10 DOI, PubMed 35181553, PMC9378754 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Comparative effectiveness of torsemide vs furosemide in the management of heart failure patients: Win-ratio reanalysis of the TRANSFORM-HF trial American heart journal, 2026-11 DOI, PubMed 42419438, PMC13450815 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial Circulation, 2023-07-11 DOI, PubMed 37212600, PMC10524905 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial JAMA, 2023-01-17 DOI, PubMed 36648467, PMC9857435 Not in the PMC Open Access subset.
  • On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF European journal of heart failure, 2024-07 DOI, PubMed 38745502, PMC11269016 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF Circulation. Heart failure, 2024-03 DOI, PubMed 38436075, PMC10950535 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03296813. Randomized; no masking; primary purpose treatment. Start 2018-07-11 (actual); primary completion 2022-07-29 (actual). Results posted on 2025-10-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure
Acronym
TRANSFORM-HF
Condition
Heart Failure
Intervention (Drug)
Torsemide
Intervention (Drug)
Furosemide
Lead sponsor
Duke University (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)
Collaborator
Yale University (class: other)

Record details

Record id
cardio:ct-nct03296813
Content hash
bce9984396e0b4a503f6de68bfaeeed197afe5a6dc18e2761c9ae60914c940f8